Ipsen is investing 60 million euros ($66 million) in an electronic autoinjector for its blockbuster cancer drug Somatuline. Facing generic competition, the French drugmaker has partnered with Phillips-Medisize on a delivery device it expects to enable patients to administer the drug independently at home.
The FDA issued its second Class I recall in as many weeks to Philips’ sleep and respiratory care segment, offering up its most serious classification.
The U.S. Food and Drug Administration on Tuesday classified the recent recall of some of Philips' ventilators as Class 1, or the most serious type of recall, saying the use of these devices may cause serious injuries or death.
AMSTERDAM, THE NETHERLANDS and TEANECK, NJ – July 8, 2021 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Cognizant (Nasdaq: CTSH), a world-leading professional services firm, today announced a new collaboration to develop end-to-end digital health solutions that will enable healthcare organizations and life sciences companies to improve patient care and accelerate clinical trials. The strategic alliance brings together Philips HealthSuite, a cloud-based platform and Cognizant’s digital engineering expertise to deliver and maintain leading-edge digital health solutions at scale, providing advanced connectivity and using big data to create actionable insights.
With 1 in 4 adults expected to have a stroke in their lives, it makes sense that Philips is kicking its stroke care offerings into high gear.
Philips’ 3D intracardiac echocardiography catheter is ready for its close-up—its extreme, in vivo close-up, that is.
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the first minimally-invasive heart procedure using its new real-time 3D intracardiac echocardiography (ICE) catheter. The Left Atrial Appendage Occlusion (LAAO) procedure was carried out by Mohamad Adnan Alkhouli, M.D., at Mayo Clinic (Minnesota, U.S.). Used together with Philips Premium Cardiology Ultrasound System (EPIQ CVx), the real-time 3D Philips Intracardiac Echocardiography Catheter – VeriSight Pro – offers superior 2D and 3D live image guidance for a wide range of procedures in structural heart disease and electrophysiology, allowing interventionalists to navigate procedures with ease, provide superior care, and optimize cath lab performance.
Developed with the Spanish center for cardiovascular research, this ultrafast technique aims to make MRI an integral option for clinical trials.
Amsterdam, the Netherlands and Madrid, Spain – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has participated in an important research project to develop a magnetic resonance (MR) imaging technique [1,2] that could potentially revolutionize the use of MR imaging in cardiology.
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the official start of the DEFINE GPS study, with the first patient being enrolled by the study’s Principal Investigator, Dr. Allen Jeremias, at St. Francis Hospital, New York (U.S.). The global, multi-center, prospective, randomized controlled DEFINE GPS study will investigate if guidance by instantaneous wave-free ratio (iFR) measurements co-registered on the angiogram demonstrates superior outcomes and improves the cost-effectiveness of percutaneous coronary intervention (PCI) procedures to open blocked coronary arteries. DEFINE GPS employs an adaptive study design, estimated to include up to 3,200 participants across 100 sites worldwide and will be one of the largest studies ever sponsored by Philips.